tbuckley/cabot-search huggingface dataset:
Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization — REVELAC-i Network, Five South American Countries, March–July 2024
Authors: Erica E. Zeno, Francisco Nogareda, Annette Regan, Paula Couto, Marc Rondy, Jorge Jara, Carla Voto, Maria Paz Rojas Mena, Nathalia Katz, Maria del Valle Juarez, Estefanía Benedetti, Francisco José de Paula Júnior, Walquiria Aparecida Ferreira da Almeida, Carlos Edson Hott, Paula Rodríguez Ferrari, Natalia Vergara Mallegas, Marcela Avendaño Vigueras, Chavely Domínguez, Marta von Horoch, Cynthia Vazquez, Eduardo Silvera, Hector Chiparelli, Natalia Goni, Laura Castro, Perrine Marcenac, Rebecca J. Kondor, Juliana Leite, Martha Velandia, Eduardo Azziz-Baumgartner, Ashley L. Fowlkes, Daniel Salas, Estefania Benedetti, Andrea Pontoriero, Maria del Valle Juarez, Nathalia Katz, Maria Paz Rojas Mena, Carla Jimena Voto, Walquiria Aparecida Ferreira da Almeida, Daiana Araújo da Silva, Francisco José de Paula Júnior, Felipe Cotrim de Carvalho, Ana Catarina de Melo Araujo, Greice Madeleine Ikeda do Carmo, Carlos Edson Hott, Miriam Teresinha Furlam Prando Livorati, Marcela Avendaño, María Fernanda Olivares Barraza, Patricia Bustos, Paula Rodríguez Ferrari, Natalia Vergara Mallegas, Rodrigo Fasce Pineda, Silvia Battaglia, Marta Von Horoch, Chavely Domínguez, Maria José Ortega, Elena Penayo, Cynthia Vázquez, Hector Chiparelli, Natalia Goñi, Karina Griot, Jose Eduardo Silvera, Daiana Tritten, Steven Tapia Villacís
Journal: MMWR Morbidity and Mortality Weekly Report (2024)

To reduce influenza-associated morbidity and mortality, countries in South America recommend annual influenza vaccination for persons at high risk for severe influenza illness, including young children, persons with preexisting health conditions, and older adults. Interim estimates of influenza vaccine effectiveness (VE) from Southern Hemisphere countries can provide early information about the protective effects of vaccination and help guide Northern Hemisphere countries in advance of their season. Using data from a multicountry network, investigators estimated interim VE against influenza-associated severe acute respiratory illness (SARI) hospitalization using a test-negative case-control design. During March 13-July 19, 2024, Argentina, Brazil, Chile, Paraguay, and Uruguay identified 11,751 influenza-associated SARI cases; on average, 21.3% of patients were vaccinated against influenza, and the adjusted VE against hospitalization was 34.5%. The adjusted VE against the predominating subtype A(H3N2) was 36.5% and against A(H1N1)pdm09 was 37.1%. These interim VE estimates suggest that although the proportion of hospitalized patients who were vaccinated was modest, vaccination with the Southern Hemisphere influenza vaccine significantly lowered the risk for hospitalization. Northern Hemisphere countries should, therefore, anticipate the need for robust influenza vaccination campaigns and early antiviral treatment to achieve optimal protection against influenza-associated complications.
Midkine as a driver of age-related changes and increase in mammary tumorigenesis
Authors: Pengze Yan, Ernesto Rojas Jimenez, Zheqi Li, Triet Bui, Marco Seehawer, Jun Nishida, Pierre Foidart, Laura E Stevens, Yingtian Xie, Miguel Munoz Gomez, So Yeon Park, Henry W Long, Kornelia Polyak
Journal: Cancer Cell (2024)
Notch4 regulatory T cells and SARS‐CoV‐2 viremia shape COVID19 survival outcome
Authors: Mehdi Benamar, Peggy S. Lai, Ching‐Ying Huang, Qian Chen, Fatma Betul Oktelik, Paola Contini, Muyun Wang, Daniel Okin, Elena Crestani, Jason Fong, Tsz Man Chan Fion, Merve Nida Gokbak, Hani Harb, Wanda Phipatanakul, Luca Marri, Chiara Vassallo, Andrea Guastalla, Minsik Kim, Hui‐Yu Sui, Lorenzo Berra, Marcia B. Goldberg, Claudia Angelini, Raffaele De Palma, Talal A. Chatila
Journal: Allergy (2024)

Immune dysregulation and SARS-CoV-2 plasma viremia have been implicated in fatal COVID-19 disease. However, how these two factors interact to shape disease outcomes is unclear. We carried out viral and immunological phenotyping on a prospective cohort of 280 patients with COVID-19 presenting to acute care hospitals in Boston, Massachusetts and Genoa, Italy between June 1, 2020 and February 8, 2022. Disease severity, mortality, plasma viremia, and immune dysregulation were assessed. A mouse model of lethal H1N1 influenza infection was used to analyze the therapeutic potential of Notch4 and pyroptosis inhibition in disease outcome. Stratifying patients based on %Notch4+ Treg cells and/or the presence of plasma viremia identified four subgroups with different clinical trajectories and immune phenotypes. Patients with both high %Notch4+ Treg cells and viremia suffered the most disease severity and 90-day mortality compared to the other groups even after adjusting for baseline comorbidities. Increased Notch4 and plasma viremia impacted different arms of the immune response in SARS-CoV-2 infection. Increased Notch4 was associated with decreased Treg cell amphiregulin expression and suppressive function whereas plasma viremia was associated with increased monocyte cell pyroptosis. Combinatorial therapies using Notch4 blockade and pyroptosis inhibition induced stepwise protection against mortality in a mouse model of lethal H1N1 influenza infection. The clinical trajectory and survival outcome in hospitalized patients with COVID-19 is predicated on two cardinal factors in disease pathogenesis: viremia and Notch4+ Treg cells. Intervention strategies aimed at resetting the immune dysregulation in COVID-19 by antagonizing Notch4 and pyroptosis may be effective in severe cases of viral lung infection.
Metformin Use and Risk of Delirium in Older Adults With Type 2 Diabetes
Authors: Mingyang Sun, Xiaoling Wang, Zhongyuan Lu, Yitian Yang, Shuang Lv, Mengrong Miao, Wan-Ming Chen, Szu-Yuan Wu, Jiaqiang Zhang
Journal: Diabetes Care (2024)

OBJECTIVE Delirium is a precursor and risk factor for dementia, emphasizing the urgency of effective prevention and management strategies in older adults with type 2 diabetes (T2D). Identifying long-term, safe, and effective medications to prevent diabetes-related delirium is crucial because of its significant impact on this population. This study aimed to evaluate the protective effects of metformin against delirium in older adults with T2D, using a competing risk analysis of death to provide a more accurate assessment. RESEARCH DESIGN AND METHODS Metformin users were compared with a cohort of nonusers. Multivariable Cox regression and Fine and Gray methods were used to assess the risk of delirium and mortality. RESULTS Our study included 66,568 metformin users and 66,568 nonusers, matched by propensity score. The use of metformin was associated with a significantly lower risk of delirium, with adjusted hazard ratios ranging from 0.77 to 0.81. A dose-response relationship was observed, indicating that higher cumulative and daily doses of metformin were associated with greater reductions in delirium risk. CONCLUSIONS Metformin use is associated with a reduced risk of delirium in older adults with T2D, with higher doses offering greater protection.
Stress triggers irritable bowel syndrome with diarrhea through a spermidine-mediated decline in type I interferon
Authors: Li Zhang, Hao-Li Wang, Ya-Fang Zhang, Xin-Tao Mao, Ting-Ting Wu, Zhi-Hui Huang, Wan-Jun Jiang, Ke-Qi Fan, Dan-Dan Liu, Bing Yang, Mei-Hui Zhuang, Guang-Ming Huang, Yinming Liang, Shu Jeffrey Zhu, Jiang-Yan Zhong, Guang-Yin Xu, Xiao-Ming Li, Qian Cao, Yi-Yuan Li, Jin Jin
Journal: Cell Metabolism (2024)
Alarmin-loaded extracellular lipid droplets induce airway neutrophil infiltration during type 2 inflammation
Authors: Zebing Rao, Shaorui Liu, Zhicheng Li, Qiuying Wang, Feng Gao, Han Peng, Deshan Ren, Yang Zang, Hui Li, Yan Li, Qi Hu, Danyang He, Heping Xu
Journal: Immunity (2024)
A simplified and robust risk stratification model for stem cell transplantation in pediatric acute myeloid leukemia
Authors: Hua Yang, Yang Xun, Yali Shen, Hongtao Wang, Yu Tao, Huihan Wang, Xinyue Zhang, Rongqiu Liu, Huarong Yu, Li Wei, Jinsong Yan, Xiaoyu Zhu, Hua You
Journal: Cell Reports Medicine (2024)
Phase II Trial of Gemcitabine and nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
Authors: Aditi Dhir, Masanori Hayashi, Avery Bodlak, Javier Oesterheld, David M. Loeb, Leo Mascarenhas, Michael S. Isakoff, Eric S. Sandler, Scott C. Borinstein, Matteo Trucco, Joanne P. Lagmay, Bhuvana A. Setty, Christine A. Pratilas, Emi Caywood, Jonathan Metts, Hong Yin, Brooke Fridley, Jun Yin, Jose Laborde, Damon R. Reed, Daniel L. Adams, Lars M. Wagner
Journal: Clinical Cancer Research (2024)

Abstract Purpose: The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease. Patients and Methods: A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response. Results: Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received &amp;gt;2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression. Conclusions: Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.
Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome
Authors: Victoria T Chu, Abigail Glascock, Deborah Donnell, Cole Grabow, Clare E Brown, Ryan Ward, Christina Love, Katrina L Kalantar, Stephanie E Cohen, Chase Cannon, Michael H Woodworth, Colleen F Kelley, Connie Celum, Anne F Luetkemeyer, Charles R Langelier
Journal: Nature Medicine (2024)
Population-specific putative causal variants shape quantitative traits
Authors: Satoshi Koyama, Xiaoxi Liu, Yoshinao Koike, Keiko Hikino, Masaru Koido, Wei Li, Kotaro Akaki, Kohei Tomizuka, Shuji Ito, Nao Otomo, Hiroyuki Suetsugu, Soichiro Yoshino, Masato Akiyama, Kohei Saito, Yuki Ishikawa, Christian Benner, Pradeep Natarajan, Patrick T Ellinor, Taisei Mushiroda, Momoko Horikoshi, Masashi Ikeda, Nakao Iwata, Koichi Matsuda, Shumpei Niida, Kouichi Ozaki, Yukihide Momozawa, Shiro Ikegawa, Osamu Takeuchi, Kaoru Ito, Chikashi Terao
Journal: Nature Genetics (2024)
Sex-specific post-inflammatory dysbiosis mediates chronic visceral pain in colitis
Authors: Maria J. Arzamendi, Yasaman B. Habibyan, Manon Defaye, Adam Shute, Cristiane H. Baggio, Ronald Chan, Christina Ohland, Dominique G. Bihan, Ian A. Lewis, Keith A. Sharkey, Kathy D. McCoy, Christophe Altier, Markus B. Geuking, Yasmin Nasser
Journal: Gut Microbes (2024)

Despite achieving endoscopic remission, over 20% of inflammatory bowel disease (IBD) patients experience chronic abdominal pain. Visceral pain and the microbiome exhibit sex-dependent interactions, while visceral pain in IBD shows a sex bias. Our aim was to evaluate whether post-inflammatory microbial perturbations contribute to visceral hypersensitivity in a sex-dependent manner.
Theta phase precession supports memory formation and retrieval of naturalistic experience in humans
Authors: Jie Zheng, Mar Yebra, Andrea G P Schjetnan, Kramay Patel, Chaim N Katz, Michael Kyzar, Clayton P Mosher, Suneil K Kalia, Jeffrey M Chung, Chrystal M Reed, Taufik A Valiante, Adam N Mamelak, Gabriel Kreiman, Ueli Rutishauser
Journal: Nature Human Behaviour (2024)
Relevance of gut microbiome research in food safety assessment
Authors: Manuel Garrido-Romero, Florencio Pazos, Elisa Sánchez-Martínez, Carlos Benito, José Ángel Gómez-Ruiz, Gonzalo Borrego-Yaniz, Cameron Bowes, Hermann Broll, Alberto Caminero, Eleonora Caro, Mónica Chagoyen, Marianne Chemaly, Antonio Fernández-Dumont, Haris Gisavi, Georgia Gkrintzali, Sangeeta Khare, Abelardo Margolles, Ana Márquez, Javier Martín, Caroline Merten, Antonia Montilla, Ana Muñoz-Labrador, Jorge Novoa, Konstantinos Paraskevopoulos, Cyrielle Payen, Helen Withers, Patricia Ruas-Madiedo, Lorena Ruiz, Yolanda Sanz, Rodrigo Jiménez-Saiz, F. Javier Moreno
Journal: Gut Microbes (2024)

The gut microbiome is indispensable for the host physiological functioning. Yet, the impact of non-nutritious dietary compounds on the human gut microbiota and the role of the gut microbes in their metabolism and potential adverse biological effects have been overlooked. Identifying potential hazards and benefits would contribute to protecting and harnessing the gut microbiome's role in supporting human health. We discuss the evidence on the potential detrimental impact of certain food additives and microplastics on the gut microbiome and human health, with a focus on underlying mechanisms and causality. We provide recommendations for the incorporation of gut microbiome science in food risk assessment and identify the knowledge and tools needed to fill these gaps. The incorporation of gut microbiome endpoints to safety assessments, together with well-established toxicity and mutagenicity studies, might better inform the risk assessment of certain contaminants in food, and/or food additives.
Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d
Authors: Namit Chaudhary, Lisa N Kasiewicz, Alexandra N Newby, Mariah L Arral, Saigopalakrishna S Yerneni, Jilian R Melamed, Samuel T LoPresti, Katherine C Fein, Daria M Strelkova Petersen, Sushant Kumar, Rahul Purwar, Kathryn A Whitehead
Journal: Nature Biomedical Engineering (2024)
A scoping review of reporting gaps in FDA-approved AI medical devices
Authors: Vijaytha Muralidharan, Boluwatife Adeleye Adewale, Caroline J Huang, Mfon Thelma Nta, Peter Oluwaduyilemi Ademiju, Pirunthan Pathmarajah, Man Kien Hang, Oluwafolajimi Adesanya, Ridwanullah Olamide Abdullateef, Abdulhammed Opeyemi Babatunde, Abdulquddus Ajibade, Sonia Onyeka, Zhou Ran Cai, Roxana Daneshjou, Tobi Olatunji
Journal: npj Digital Medicine (2024)
EXPANDING HIV-1 DIVERSITY IN RUSSIA: NOVEL CIRCULATING RECOMBINANT FORM BETWEEN SUBTYPES A6 AND B (CRF147_A6B)
Authors: Lada V Maksimenko, Mariya V Sivay, Maria E Antonets, Tatiana V Tregubchak, Alexei V Totmenin, Sergei E Skudarnov, Tatiana S Ostapova, Svetlana V Yashenko, Aleksander P Agafonov, Natalia M Gashnikova
Journal: Journal of Infection (2024)
Revascularization and outcomes in ischaemic left ventricular dysfunction after heart failure admission: The <scp>RevascHeart</scp> study
Authors: Carlos Moliner‐Abós, Maria Calvo‐Barceló, Eduard Solé‐Gonzalez, Andrea Borrellas Martín, Paula Fluvià‐Brugués, Jesús Sánchez‐Vega, Joan Vime‐Jubany, Maria Ferré Vallverdú, Manel Taurón Ferrer, Pablo E. Tobias‐Castillo, Juan Carlos de la Fuente Mancera, Pau Vilardell‐Rigau, Rosa Vila‐Olives, Carles Diez‐López, Antoni Bayés‐Genís, Dabit Arzamendi Aizpurua, Ignacio Ferreira‐Gonzalez, Sònia Mirabet Pérez
Journal: European Journal of Heart Failure (2024)
Multicentre, randomized, double‐blind, prospective study on the effects of <scp>ImmunoAdSorptiOn</scp> on cardiac function in patients with Dilated <scp>CardioMyopathy</scp> (<scp>IASO</scp>‐<scp>DCM</scp>): Rationale and design
Authors: Marcus Dörr, Michael Böhm, Erland Erdmann, Stefan Groß, Amir‐Abbas Mahabadi, Matthias Nauck, Georg Nickening, Heinz‐Peter Schultheiss, Alexander Staudt, Karl Werdan, Finn Waagstein, Åke Hjalmarson, Stephan B. Felix
Journal: European Journal of Heart Failure (2024)
A Multifunctional Nanodrug Increases the Therapeutic Sensitivity of Lenvatinib to Hepatocellular Carcinoma by Inhibiting the Stemness of Hepatic Cancer Stem Cells
Authors: Xieqing Yang, Qiaoyun Zhang, Dongye Li, Lanxin Hu, Yu Wang, Xinyu Yan, Yunhua Li, Yong Wang, Fang Zhang, Jun Shen
Journal: Advanced Healthcare Materials (2024)

Abstract Drug resistance resulting from diverse mechanisms including the presence of cancer stem cells (CSCs) is the main obstacle for improving therapeutic efficacy of lenvatinib in hepatocellular carcinoma (HCC). Herein, a nanomedicine (siCD24‐Len‐MnO@PLAP) is developed by incorporating manganese oxide (MnO), lenvatinib (Len), and siRNA against CD24 (siCD24) into micelles composed of methoxypolyethylene glycol ( m PEG), poly‐L‐lysine (PLLys), and polyasparagyl(N‐(2‐Aminoethyl)piperidine) (PAsp(PIP)) triblock copolymer. The nanomedicine can respond to the tumor microenvironment (TME) to release lenvatinib, and produce Mn 2+ and O 2 , accompanied by changes in nanoparticle charge, which facilitates cellular endocytosis of siCD24‐loaded nanoparticles. The released siCD24 and lenvatinib synergistically reduces CD24 expression, resulting in a more pronounced inhibition of stemness of CSCs. In the mouse models of HCC using Huh7‐derived CSCs and Hepa1‐6‐derived CSCs, the nanomedicine shows remarkable anti‐cancer effect by enhancing the therapeutic effects of lenvatinib against HCC via reducing the expression level of CD24 and decreasing the expression of hypoxia inducible factor‐1α (HIF‐1α). Moreover, in situ production of paramagnetic Mn 2+ from the nanomedicine serves as an excellent contrast agent for magnetic resonance imaging (MRI) to monitor the therapeutic process. This study demonstrates that this multifunctional MRI‐visible siCD24‐ and lenvatinib‐loaded nanodrug holds great potential in enhancing therapeutic sensitivity for HCC lenvatinib therapy.
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection
Authors: Chen-Hua Liu, Pin-Nan Cheng, Yu-Jen Fang, Chi-Yi Chen, Wei-Yu Kao, Chih-Lin Lin, Sheng-Shun Yang, Yu-Lueng Shih, Cheng-Yuan Peng, Yu-Ping Chang, Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
Journal: Journal of Hepatology (2024)
Self-testing strategy to eliminate Hepatitis C as per WHO’s goal: Analysis of disease burden and cost-effectiveness
Authors: Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
Journal: Clinical and Molecular Hepatology (2024)

The World Health Organization (WHO) aims to eliminate hepatitis C Virus (HCV) by 2030, therefore, widespread HCV screening is required. The WHO recommends HCV self-testing (HCVST) as a new approach. We aimed to evaluate disease burden reduction using the HCVST screening strategy and identify the most cost-effective approach.
Intraoperative Aberrometry versus Preoperative Biometry for Intraocular Lens Power Calculations
Authors: Seth M Pantanelli, Kathryn Hatch, Charles C Lin, W Allan Steigleman, Zaina Al-Mohtaseb, Jennifer R Rose-Nussbaumer, Marcony R Santhiago, Tiarnán D L Keenan, Stephen J Kim, Deborah S Jacobs, Julie M Schallhorn
Journal: Ophthalmology (2024)
Ironing Out the Kinks: Arming Natural Killer Cells against Ovarian Cancer
Authors: Hannah Noelle Bell, Weiping Zou
Journal: Cancer Discovery (2024)

Ameliorating the tumor immune microenvironment is a key strategy to improve the therapeutic outcomes of patients with cancer. Sandoval and colleagues demonstrate that iron chelation enhances type I IFN production, promotes NK cell tumor trafficking and activation, and synergizes with chemotherapy drug cisplatin to reduce metastatic ovarian cancer progression in murine models. See related article by Sandoval et al., p. 1901.
Cancer Genomes Sometimes Take the Longest Evolutionary Road
Authors: Alison M. Taylor
Journal: Cancer Discovery (2024)

Baker and colleagues developed a new algorithm called "Gain Route Identification and Timing In Cancer" (GRITIC) to uncover the path of chromosomal evolution in a tumor, particularly in the context of whole-genome duplication. Their approach found that tumors with genome doubling frequently take an indirect path from one copy number state to another. In addition, the timing of genome doubling within a tumor's evolution impacts its consequences on downstream chromosomal instability. See related article by Baker et al., p. 1810.
Can Ruxolitinib Crash <i>TET2</i>- and <i>IDH2</i>-Driven Clonal Hematopoiesis?
Authors: Elmira Khabusheva, Margaret A. Goodell
Journal: Cancer Discovery (2024)

In this issue, Waarts and colleagues developed an advanced ex vivo CRISPR screening platform to identify vulnerabilities in clonal hematopoiesis (CH). This unique system allowed the authors to identify a link between IDH2 and TET2 CH mutations, histone demethylases, and altered cytokine signaling, which enabled targeting by ruxolitinib leading to the elimination of CH clones, offering a possible path for preventing the development of malignancy. See related article by Waarts et al., p. 1860.
Clinical glycoproteomics: methods and diseases
Authors: Yujia Wang, Kaixin Lei, Lijun Zhao, Yong Zhang
Journal: MedComm (2024)

Abstract Glycoproteins, representing a significant proportion of posttranslational products, play pivotal roles in various biological processes, such as signal transduction and immune response. Abnormal glycosylation may lead to structural and functional changes of glycoprotein, which is closely related to the occurrence and development of various diseases. Consequently, exploring protein glycosylation can shed light on the mechanisms behind disease manifestation and pave the way for innovative diagnostic and therapeutic strategies. Nonetheless, the study of clinical glycoproteomics is fraught with challenges due to the low abundance and intricate structures of glycosylation. Recent advancements in mass spectrometry‐based clinical glycoproteomics have improved our ability to identify abnormal glycoproteins in clinical samples. In this review, we aim to provide a comprehensive overview of the foundational principles and recent advancements in clinical glycoproteomic methodologies and applications. Furthermore, we discussed the typical characteristics, underlying functions, and mechanisms of glycoproteins in various diseases, such as brain diseases, cardiovascular diseases, cancers, kidney diseases, and metabolic diseases. Additionally, we highlighted potential avenues for future development in clinical glycoproteomics. These insights provided in this review will enhance the comprehension of clinical glycoproteomic methods and diseases and promote the elucidation of pathogenesis and the discovery of novel diagnostic biomarkers and therapeutic targets.